Study Number: I11054
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

C Number: I11054
Study Gender: Female
PWG Approval Date: See web page for date of PWG Approval

M11: Spleen Cell Proliferative Response to Anti-CD3 Stimulation
Test Compound: Sulfolane
CAS Number: 126-33-0

Date Report Requested: 09/12/2018
Time Report Requested: 08:57:28
Lab: Burleson Research Technologies
## Females

<table>
<thead>
<tr>
<th>Treatment Groups (mg/kg)</th>
<th>0</th>
<th>1</th>
<th>10</th>
<th>30</th>
<th>100</th>
<th>300</th>
<th>50 mg/kg CPS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.056 ± 0.187 (8) *</td>
<td>2.019 ± 0.187 (8)</td>
<td>1.630 ± 0.117 (8)</td>
<td>1.650 ± 0.121 (8)</td>
<td>1.719 ± 0.112 (8)</td>
<td>1.503 ± 0.181 (8)</td>
<td>1.426 ± 0.147 (8) *</td>
</tr>
</tbody>
</table>
**LEGEND**

Data are displayed as mean ± SEM (N) unless otherwise noted.

Stimulation index determined by comparing the mean stimulated proliferation value to the proliferative value in cells with no stimulation

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests (unless otherwise noted).

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

CPS = Cyclophosphamide

**END OF REPORT**